<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30185598</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>23</Issue><PubDate><Year>2018</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00556-18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00556-18</ELocationID><Abstract><AbstractText>The four serotypes of dengue virus (DENV) cause the most important mosquito-borne viral disease in humans. The envelope (E) protein is the major target of neutralizing antibodies and contains 3 domains (domain I [DI], DII, and DIII). Recent studies reported that human monoclonal antibodies (MAbs) recognizing DIII, the D1/DII hinge, the E-dimer epitope, or a quaternary epitope involving DI/DII/DIII are more potently neutralizing than those recognizing the fusion loop (FL) of DII. Due to inefficient cleavage of the premembrane protein, DENV suspensions consist of a mixture of mature, immature, and partially immature particles. We investigated the neutralization and binding of 22 human MAbs to DENV serotype 1 (DENV1) virions with differential maturation status. Compared with FL MAbs, DIII, DI/DII hinge, and E-dimer epitope MAbs showed higher maximum binding and avidity to mature particles relative to immature particles; this feature may contribute to the strong neutralizing potency of such MAbs. FL-specific MAbs required 57 to 87% occupancy on mature particles to achieve half-maximal neutralization (NT<sub>50</sub>), whereas the potently neutralizing MAbs achieved NT<sub>50</sub> states at 20 to 38% occupancy. Analysis of the MAb repertoire and polyclonal sera from patients with primary DENV1 infection supports the immunodominance of cross-reactive anti-E antibodies over type-specific antibodies. After depletion with viral particles from a heterologous DENV serotype, the type-specific neutralizing antibodies remained and showed binding features shared by potent neutralizing MAbs. Taken together, these findings suggest that the use of homogeneous mature DENV particles as an immunogen may induce more potent neutralizing antibodies against DENV than the use of immature or mixed particles.<b>IMPORTANCE</b> With an estimated 390 million infections per year, the four serotypes of dengue virus (DENV) cause the most important mosquito-borne viral disease in humans. The dengue vaccine Dengvaxia was licensed; however, its low efficacy among dengue-naive individuals and increased risk of causing severe dengue in children highlight the need for a better understanding of the role of human antibodies in immunity against DENV. DENV suspensions contain mature, immature, and partially immature particles. We investigated the binding of 22 human monoclonal antibodies (MAbs) to the DENV envelope protein on particles with different maturation states. Potently neutralizing MAbs had higher relative maximum binding and avidity to mature particles than weakly neutralizing MAbs. This was supported by analysis of MAb repertoires and polyclonal sera from patients with primary DENV infection. Together, these findings suggest that mature particles may be the optimal form of presentation of the envelope protein to induce more potent neutralizing antibodies against DENV.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wen-Yang</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui-Ling</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jih-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Dengue Fever Control and Research, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dejnirattisai</LastName><ForeName>Wanwisa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jumnainsong</LastName><ForeName>Amonrat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mongkolsapaya</LastName><ForeName>Juthathip</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Screaton</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>James E</ForeName><Initials>JE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Kung</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA wangwk@hawaii.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>095541/Z/11/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 GM114737</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI106695</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>203224/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI110769</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AI149502</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">envelope</Keyword><Keyword MajorTopicYN="N">mature particles</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30185598</ArticleId><ArticleId IdType="pmc">PMC6232466</ArticleId><ArticleId IdType="doi">10.1128/JVI.00556-18</ArticleId><ArticleId IdType="pii">JVI.00556-18</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman MG, Harris E. 2015. Dengue. Lancet 385:453&#x2013;465. doi:10.1016/S0140-6736(14)60572-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60572-9</ArticleId><ArticleId IdType="pubmed">25230594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504&#x2013;507. doi:10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 2009. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control, 3rd ed World Health Organization, Geneva, Switzerland.</Citation></Reference><Reference><Citation>Murphy BR, Whitehead SS. 2011. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587&#x2013;619. doi:10.1146/annurev-immunol-031210-101315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101315</ArticleId><ArticleId IdType="pubmed">21219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Briand O, Lang J, Saville M, Jackson N. 2015. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33:7100&#x2013;7111. doi:10.1016/j.vaccine.2015.09.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.108</ArticleId><ArticleId IdType="pubmed">26475445</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro SR, Arredondo-Garc&#xed;a JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cort&#xe9;s M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, CYD-TDV Dengue Vaccine Working Group 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195&#x2013;1206. doi:10.1056/NEJMoa1506223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506223</ArticleId><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T. 2016. Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine. J Infect Dis 214:1796&#x2013;1799. doi:10.1093/infdis/jiw341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw341</ArticleId><ArticleId IdType="pubmed">27496977</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. 2016. Critique of World Health Organization recommendation of a dengue vaccine. J Infect Dis 214:1793&#x2013;1795. doi:10.1093/infdis/jiw340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw340</ArticleId><ArticleId IdType="pubmed">27496975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanofi. 2017. Sanofi updates information on dengue vaccine. Press release, 30 November Sanofi, Paris, France.</Citation></Reference><Reference><Citation>Pierson TC, Diamond MS. 2013. Flaviviruses, p 747&#x2013;794. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 6th ed Lippincott William &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313&#x2013;319. doi:10.1038/nature02165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02165</ArticleId><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75:7769&#x2013;7773. doi:10.1128/JVI.75.16.7769-7773.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7769-7773.2001</ArticleId><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, S&#xe1;nchez-San Mart&#xed;n C, Zheng A, Kielian M. 2010. In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein. J Virol 84:5730&#x2013;5740. doi:10.1128/JVI.00170-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00170-10</ArticleId><ArticleId IdType="pmc">PMC2876590</ArticleId><ArticleId IdType="pubmed">20335260</ArticleId></ArticleIdList></Reference><Reference><Citation>Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70:37&#x2013;43. doi:10.1099/0022-1317-70-1-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-1-37</ArticleId><ArticleId IdType="pubmed">2543738</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991. doi:10.1371/journal.pone.0004991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349&#x2013;360. doi:10.1016/j.virol.2007.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.05.042</ArticleId><ArticleId IdType="pubmed">17719070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin K, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816&#x2013;12826. doi:10.1128/JVI.00432-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00432-07</ArticleId><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin K, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823. doi:10.1371/journal.ppat.1000823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK. 2012. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high-throughput assay. PLoS Negl Trop Dis 6:e1447. doi:10.1371/journal.pntd.0001447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001447</ArticleId><ArticleId IdType="pmc">PMC3250511</ArticleId><ArticleId IdType="pubmed">22235356</ArticleId></ArticleIdList></Reference><Reference><Citation>Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. 2013. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 87:52&#x2013;66. doi:10.1128/JVI.02273-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02273-12</ArticleId><ArticleId IdType="pmc">PMC3536401</ArticleId><ArticleId IdType="pubmed">23077306</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Lai CY, Wu YC, Lin HE, Edwards E, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK. 2013. High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 87:12562&#x2013;12575. doi:10.1128/JVI.00871-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00871-13</ArticleId><ArticleId IdType="pmc">PMC3838129</ArticleId><ArticleId IdType="pubmed">24027331</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-13. doi:10.1128/mBio.00873-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00873-13</ArticleId><ArticleId IdType="pmc">PMC3870244</ArticleId><ArticleId IdType="pubmed">24255124</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey RA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271&#x2013;283. doi:10.1016/j.chom.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brian J, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. doi:10.1371/journal.pntd.0001188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001188</ArticleId><ArticleId IdType="pmc">PMC3119640</ArticleId><ArticleId IdType="pubmed">21713020</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439&#x2013;7444. doi:10.1073/pnas.1200566109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh EP, Kukkaro PP, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra83. doi:10.1126/scitranslmed.3003888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003888</ArticleId><ArticleId IdType="pubmed">22723463</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. 2014. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 88:12233&#x2013;12241. doi:10.1128/JVI.00247-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00247-14</ArticleId><ArticleId IdType="pmc">PMC4248927</ArticleId><ArticleId IdType="pubmed">25100837</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE Jr, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358&#x2013;371. doi:10.1002/emmm.201303404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303404</ArticleId><ArticleId IdType="pmc">PMC3958310</ArticleId><ArticleId IdType="pubmed">24421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE Jr, Lok SM. 2015. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349:88&#x2013;91. doi:10.1126/science.aaa8651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8651</ArticleId><ArticleId IdType="pmc">PMC4672004</ArticleId><ArticleId IdType="pubmed">26138979</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. doi:10.1038/ncomms7341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7341</ArticleId><ArticleId IdType="pmc">PMC4346626</ArticleId><ArticleId IdType="pubmed">25698059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170&#x2013;177. doi:10.1038/ni.3058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3058</ArticleId><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Despr&#xe8;s P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109&#x2013;113. doi:10.1038/nature14130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14130</ArticleId><ArticleId IdType="pubmed">25581790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kielian M, Rey FA. 2006. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4:67&#x2013;76. doi:10.1038/nrmicro1326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1326</ArticleId><ArticleId IdType="pmc">PMC7097298</ArticleId><ArticleId IdType="pubmed">16357862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3:13&#x2013;22. doi:10.1038/nrmicro1067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1067</ArticleId><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834&#x2013;1837. doi:10.1126/science.1153264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153264</ArticleId><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera R, Kuhn RJ. 2008. Structural proteomics of dengue virus. Curr Opin Microbiol 11:369&#x2013;377. doi:10.1016/j.mib.2008.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2008.06.004</ArticleId><ArticleId IdType="pmc">PMC2581888</ArticleId><ArticleId IdType="pubmed">18644250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 28:3269&#x2013;3276. doi:10.1038/emboj.2009.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.245</ArticleId><ArticleId IdType="pmc">PMC2771083</ArticleId><ArticleId IdType="pubmed">19713934</ArticleId></ArticleIdList></Reference><Reference><Citation>Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, Keelapang P, Puttikhunt C, Perera R, Chipman PR, Kasinrerk W, Malasit P, Kuhn RJ, Sittisombut N. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol 84:8353&#x2013;8358. doi:10.1128/JVI.00696-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00696-10</ArticleId><ArticleId IdType="pmc">PMC2916513</ArticleId><ArticleId IdType="pubmed">20519400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM. 2008. Functional importance of dengue virus maturation: infectious properties of immature virions. J Gen Virol 89:3047&#x2013;3051. doi:10.1099/vir.0.2008/002535-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002535-0</ArticleId><ArticleId IdType="pubmed">19008392</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, Smit JM. 2010. Immature dengue virus: a veiled pathogen? PLoS Pathog 6:e1000718. doi:10.1371/journal.ppat.1000718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000718</ArticleId><ArticleId IdType="pmc">PMC2798752</ArticleId><ArticleId IdType="pubmed">20062797</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Durbin A, Tsai JJ, Whitehead S, Wang WK. 2015. Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol 89:7348&#x2013;7362. doi:10.1128/JVI.00273-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00273-15</ArticleId><ArticleId IdType="pmc">PMC4473561</ArticleId><ArticleId IdType="pubmed">25972550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu SP, King CC, Wu HC, Wang WK. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631&#x2013;6643. doi:10.1128/JVI.00316-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK. 2013. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7:e2451. doi:10.1371/journal.pntd.0002451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002451</ArticleId><ArticleId IdType="pmc">PMC3777924</ArticleId><ArticleId IdType="pubmed">24069496</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828&#x2013;8837. doi:10.1128/JVI.00606-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00606-08</ArticleId><ArticleId IdType="pmc">PMC2519678</ArticleId><ArticleId IdType="pubmed">18562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135&#x2013;145. doi:10.1016/j.chom.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229&#x2013;238. doi:10.1016/j.chom.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9:e1003761. doi:10.1371/journal.ppat.1003761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003761</ArticleId><ArticleId IdType="pmc">PMC3857832</ArticleId><ArticleId IdType="pubmed">24348242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS. 2015. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6:e01461-15. doi:10.1128/mBio.01461-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01461-15</ArticleId><ArticleId IdType="pmc">PMC4620467</ArticleId><ArticleId IdType="pubmed">26463165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM. 2017. Mapping the human memory B cell and serum neutralizing antibody responses to dengue virus serotype 4 infection and vaccination. J Virol 91:e02041-16. doi:10.1128/JVI.02041-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02041-16</ArticleId><ArticleId IdType="pmc">PMC5309932</ArticleId><ArticleId IdType="pubmed">28031369</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E. 2017. Analysis of individuals from a dengue-endemic region helps define the footprint and repertoire of antibodies targeting dengue virus 3 type-specific epitopes. mBio 8:e01205-17. doi:10.1128/mBio.01205-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01205-17</ArticleId><ArticleId IdType="pmc">PMC5605938</ArticleId><ArticleId IdType="pubmed">28928210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Lin HE, Wang WK. 2017. Complexity of human antibody response to dengue virus: implication for vaccine development. Front Microbiol 8:1372. doi:10.3389/fmicb.2017.01372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01372</ArticleId><ArticleId IdType="pmc">PMC5517401</ArticleId><ArticleId IdType="pubmed">28775720</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz SW, Gallichotte EN, Brackbill A, Premkumar L, Miley MJ, Baric R, de Silva AM. 2017. In vitro assembly and stabilization of dengue and Zika virus envelope protein homo-dimers. Sci Rep 7:4524. doi:10.1038/s41598-017-04767-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04767-6</ArticleId><ArticleId IdType="pmc">PMC5495877</ArticleId><ArticleId IdType="pubmed">28674411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney MC, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, Mongkolsapaya J, Rey FA, Screaton GR. 2017. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat Commun 8:15411. doi:10.1038/ncomms15411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15411</ArticleId><ArticleId IdType="pmc">PMC5457521</ArticleId><ArticleId IdType="pubmed">28534525</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE Jr. 2015. Dengue virus prM-specific human monoclonal antibodies with virus replication enhancing properties recognize a single immunodominant antigenic site. J Virol 90:780&#x2013;789. doi:10.1128/JVI.01805-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01805-15</ArticleId><ArticleId IdType="pmc">PMC4702676</ArticleId><ArticleId IdType="pubmed">26512092</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. 2014. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386. doi:10.1371/journal.ppat.1004386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004386</ArticleId><ArticleId IdType="pmc">PMC4183589</ArticleId><ArticleId IdType="pubmed">25275316</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol 88:11726&#x2013;11737. doi:10.1128/JVI.01140-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01140-14</ArticleId><ArticleId IdType="pmc">PMC4178732</ArticleId><ArticleId IdType="pubmed">25078693</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller BA, Bett AJ. 2015. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine 33:4105&#x2013;4116. doi:10.1016/j.vaccine.2015.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.067</ArticleId><ArticleId IdType="pubmed">26144900</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>